Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905899 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL7688672 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL8125876 | 0.85 | POLB (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL6903558 | 0.85 | POLB (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL7349213 | 0.85 | POLB (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL6903563 | 0.85 | POLB (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL31163362 | 0.83 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL665345 | 0.83 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL8297473 | 0.83 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL10265619 | 0.82 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015441-B1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | UPJOHN CO (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1015441-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1999012919-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
| US-20090062346-A1 | DEUTERIUM-ENRICHED TIPRANAVIR | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062346-A1 | DEUTERIUM-ENRICHED TIPRANAVIR | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1015441-B1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | UPJOHN CO (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6265604-B1 | AS PROTEASE INHIBITOR USEFUL IN TREATING HUMANS INFECTED WITH THE HIV VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-1015441-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6077963-A | Process to produce a protease inhibitor | PHARMACIA & UPJOHN COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| WO-1999012919-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062346-A1 | DEUTERIUM-ENRICHED TIPRANAVIR | SAMHD1, NSD3, NSD1 | MEN1 3966/4885KMT2A 1215/4885ALDH1A1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.